BIO-TECHNE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.06 USD | +2.23% |
|
+3.12% | -16.98% |
| 04-26 | Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay | CI |
| 04-23 | Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe | MT |
| Sales 2024 * | 1.15B 91.8B | Sales 2025 * | 1.25B 99.69B | Capitalization | 10.07B 806B |
|---|---|---|---|---|---|
| Net income 2024 * | 179M 14.33B | Net income 2025 * | 229M 18.34B | EV / Sales 2024 * | 8.95 x |
| Net Debt 2024 * | 187M 14.96B | Net cash position 2025 * | 10.85M 868M | EV / Sales 2025 * | 8.08 x |
| P/E ratio 2024 * |
57.7
x | P/E ratio 2025 * |
45.1
x | Employees | 3,050 |
| Yield 2024 * |
0.5% | Yield 2025 * |
0.5% | Free-Float | 99.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bio-Techne Corporation
More recommendations
More press releases
| 1 day | +2.23% | ||
| 1 week | +3.12% | ||
| Current month | -8.99% | ||
| 1 month | -7.72% | ||
| 3 months | -11.80% | ||
| 6 months | +7.59% | ||
| Current year | -16.98% |
1 week
61.79
64.59
1 month
61.1671.27
Current year
61.1678.75
1 year
51.7989.91
3 years
51.79135.96
5 years
38.79135.96
10 years
19.99135.96
| Managers | Title | Age | Since |
|---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 29/04/18 |
James Hippel
DFI | Director of Finance/CFO | 53 | 31/03/14 |
Matthew McManus
COO | Chief Operating Officer | 55 | 01-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 31/12/02 | |
Randolph Steer
BRD | Director/Board Member | 74 | 31/12/89 |
Joseph Keegan
BRD | Director/Board Member | 71 | 25/10/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.93% | 1 M€ | -5.79% | - | |
| 2.50% | 5 M€ | -1.80% | - | |
| 2.15% | 2 M€ | -.--% | ||
| 1.25% | 0 M€ | 0.00% | - | |
| 1.13% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 64.06 | +2.23% | 973,784 |
| 25/04/24 | 62.66 | -1.35% | 965,762 |
| 24/04/24 | 63.52 | -0.27% | 984,815 |
| 23/04/24 | 63.69 | +1.42% | 1,217,190 |
| 22/04/24 | 62.8 | +1.09% | 829,547 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows:
- biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.;
- diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc.
Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Calendar
01/05/2024
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
64.06
USD
Average target price
80.43
USD
Spread / Average Target
+25.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.98% | 10.07B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TECH Stock
